Status and phase
Conditions
Treatments
About
n this study, approximately 30 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) were recruited for a single reinfusion of IM19-CD28 and IM19-41BB CAR-T cells. Assess the safety, tolerability of treatment, and initially observe the efficacy.
Full description
Dose-escalation:Patients entered the IM19-41BB or IM19-CD28 group and performed dose escalation studies in three dose groups. According to the results of the previous dose escalation study, select one dose to continue the enrollment of 6 patients for extended studies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Xin-an Lu, Dr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal